Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"FYN Kinase-Mediated Synaptic Signaling Cascade\",\n      \"mechanism\": \"Aβ oligomers activate FYN kinase at the postsynaptic density, which phosphorylates both NMDA receptors (enhancing excitotoxicity) and tau (promoting missorting), creating a pathogenic feedforward loop that persists independent of Aβ burden.\",\n      \"target_gene\": \"FYN\",\n      \"confidence_score\": 0.6,\n      \"novelty_score\": 0.7,\n      \"feasibility_score\": 0.7,\n      \"impact_score\": 0.9,\n      \"composite_score\": 0.70,\n      \"testable_prediction\": \"FYN knockout or pharmacological inhibition in 5xFAD mice will block tau missorting to dendrites even when Aβ accumulation continues unchanged.\",\n      \"skeptic_concern\": \"Causal direction ambiguous—FYN activation could be downstream consequence rather than driver of Aβ toxicity.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Kinase-Phosphatase Set-Point Disruption\",\n      \"mechanism\": \"Aβ burden shifts the kinase/phosphatase equilibrium toward tau hyperphosphorylation by simultaneously upregulating GSK3β/CDK5 activity and downregulating PP2A function, locking tau into a pathogenic phosphorylation state.\",\n      \"target_gene\": \"GSK3B\",\n      \"confidence_score\": 0.7,\n      \"novelty_score\": 0.5,\n      \"feasibility_score\": 0.7,\n      \"impact_score\": 0.8,\n      \"composite_score\": 0.68,\n      \"testable_prediction\": \"Sustained PP2A activation in Aβ-producing mice will prevent formation of hyperphosphorylated tau oligomers despite ongoing amyloid deposition.\",\n      \"skeptic_concern\": \"Redundancy among tau kinases may limit therapeutic efficacy of single-target inhibitors.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Prion-Like Cross-Seeding via Oligomer Interfaces\",\n      \"mechanism\": \"Aβ*56 oligomers expose cryptic β-strand domains that template tau R2/R3 repeat domain conversion into β-sheet-rich nuclei, bypassing homogeneous nucleation and explaining the temporal sequence of Aβ preceding tau spreading.\",\n      \"target_gene\": \"None\",\n      \"confidence_score\": 0.5,\n      \"novelty_score\": 0.6,\n      \"feasibility_score\": 0.4,\n      \"impact_score\": 0.8,\n      \"composite_score\": 0.58,\n      \"testable_prediction\": \"Co-immunoprecipitation of Aβ*56 with misfolded tau species from human AD brain tissue will demonstrate stable physical interaction absent from age-matched controls.\",\n      \"skeptic_concern\": \"Structural basis for the claimed interface remains uncharacterized; in vitro cross-seeding requires non-physiological concentrations.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"Aβ-tau synergy is necessary to explain both Alzheimer's disease progression and anti-Aβ trial failures\",\n    \"Tau pathology is downstream of Aβ but becomes self-propagating and Aβ-independent\",\n    \"Multi-target approaches will likely outperform monotherapies targeting either protein in isolation\"\n  ],\n  \"dissent_points\": [\n    \"Timing windows differ by mechanism—cross-seeding may require intervention before Aβ accumulation, while kinase/phosphatase disruption could work post-symptomatically\"\n  ],\n  \"debate_summary\": \"The debate converges on Aβ-tau synergy as the critical pathogenic mechanism explaining why amyloid-targeting monotherapies fail, with expert ranking favoring downstream effector pathways (FYN signaling, kinase-phosphatase imbalance) over upstream nucleation events due to superior translational potential and broader therapeutic windows. The prion-like cross-seeding hypothesis remains mechanistically compelling but faces structural validation challenges that limit near-term clinical translation.\"\n}",
  "tokens_used": "903"
}